Weekly Epidemiological Record, 25 January 2019, vol. 94, 4 - Global Vaccine Safety meeting: Safety of typhoid conjugate vaccine

Overview

GACVS previously reviewed the safety of typhoid vaccines, including the newer generation of typhoid conjugate vaccines (TCVs), in December 2016.3 The Committee noted that its conclusions and recommendations formed part of the evidence reviewed by the Strategic Advisory Group of Experts (SAGE) on immunization for a revised policy and an updated WHO position paper on the use of typhoid vaccines, issued in March 2018.4 The new position paper includes the first recommendation for routine use of TCV as a single intramuscular dose for primary vaccination of infants and children from 6 months of age and adults ≤45 years of age and in catch-up campaigns in children ≤15 years of age in typhoid-endemic regions. Further, TCV is recommended for the control of typhoid in epidemic settings.